Red Cross Asks FDA To Let False-Positive Blood Donors Back In The Pool
This article was originally published in The Gray Sheet
Executive Summary
FDA should include blood donor re-entry algorithms under investigational new drug applications for nucleic acid test (NAT) screening for hepatitis C (HCV) and HIV, according to the American Red Cross.